Psoriasis is a common, immunologically mediated, inflammatory and hyperproliferative disease of the skin and joints, with a multifactorial genetic basis. We earlier mapped PSORS1, the major psoriasis susceptibility gene in the major histocompatibility complex (MHC), to within or very near HLA-Cw6. In an effort to identify non-MHC psoriasis genes, we carried out a collaborative genome-wide association study. After the initial follow-up genotyping of 21 single nucleotide polymorphisms from 18 loci, showing strong evidence of association in the initial scan, we confirmed evidence of association at seven loci. Three of these loci confirm earlier reports of association (HLA-C, IL12B, IL23R) and four identify novel signals located near plausible candidate genes (IL23A, IL4/IL13, TNFAIP3 and TNIP1). In other work, we have also shown that interferon-g (IFN-g) treatment induces interleukin (IL)-23 mRNA and protein in antigen-presenting cells (APC), leading to the proliferation of CD4 þ and CD8þ memory T cells expressing IL-17. Although functional variants remain to be identified, we speculate that genetic variants at the IL4/IL13 locus contribute to the Th1 bias that is characteristic of psoriasis, that Th1-derived IFN-g supports expansion of IL-17 þ T cells through APC-derived IL-23 and that negative regulation of inflammatory signaling through the NF-kB axis is impaired because of genetic variants of TNFAIP3 and TNIP1.
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The cutaneous manifestations of psoriasis are unpleasant and obvious, with a very negative impact on quality of life. 2 The majority of the 150 000 new US cases diagnosed annually arise in individuals o30 years of age, and 10 000 of these are in individuals o10 years old. 3 Moreover, up to 40% of psoriatics develop psoriatic arthritis (PsA), and in 5% of them the arthritis is severe and deforming. 4 The clinical and genetic epidemiology of psoriasis has been reviewed in detail [5] [6] [7] [8] and will be only briefly considered here. Two forms of psoriasis differing in age of onset have been proposed, with early onset disease (onset p40 years) more likely to be familial, severe and associated with HLA-Cw6. 9 The peak age of disease onset is the early twenties. Twin studies, pedigree studies and recurrence risk analysis support a multifactorial model of inheritance, with a major susceptibility locus (psoriasis susceptibility 1 or PSORS1) residing within the major histocompatibility complex (MHC) and other loci residing throughout the genome. There is clearly a role for environmental factors, such as trauma, stress and infections such as streptococcal pharyngitis (for review, see 5 ). PsA is even more strongly influenced by genes than is psoriasis vulgaris. 10, 11 The clinical variants of psoriasis include chronic plaque psoriasis, guttate psoriasis, localized pustular psoriasis, inverse psoriasis, sebopsoriasis and generalized pustular psoriasis, as well as palmoplantar pustulosis. Chronic plaque disease is by far the most common form. The clinical manifestations of psoriasis can change over time in any given person. Nail changes (pitting, onychodystrophy and/or 'oil drop' spotting) are found in around 50% of psoriasis patients. Guttate psoriasis is characterized by the sudden appearance of hundreds of small papules, with spontaneous resolution in approximately half of cases, and with the other half progressing to chronic plaque psoriasis. The association of guttate psoriasis with HLA-Cw6 is even stronger than it is for chronic plaque psoriasis. 12 Generalized pustular psoriasis manifests the same HLA (human leukocyte antigen) associations found in plaque-type psoriasis. 13 In contrast, palmoplantar pustulosis is not associated with HLA-Cw6 14 and is only rarely associated with typical psoriatic plaques. Therefore, it seems to be a distinct entity. PsA typically presents between the ages of 35 and 45, usually, but not always, after onset of skin disease. Disease is oligoarticular and asymmetrical in over 80% of patients.
The Th1-Th17 axis: new insights into psoriasis pathogenesis Recently, there has been a major expansion of knowledge that may provide specific insights into the link between immunocytic infiltration and epidermal hyperplasia. A new subset of T cells expressing interleukin (IL)-17 seems to play a major role in psoriasis 15 as well as other inflammatory autoimmune disorders, including multiple sclerosis 16 and Crohn's disease. 17 IL-23 drives this novel immune circuit. It is produced by myeloid cells and acts on T cells through its cognate receptor. IL-12 and IL-23 share the p40 subunit, encoded by the IL12B gene. The p40 subunit heterodimerizes with p19 to form IL-12, and with p35 to form IL-23. The IL-12 and IL-23 receptors share the common IL12Rb1 subunit, which binds to IL12Rb2 to form the IL-12 receptor and to the product of the IL23R gene to form the IL-23 receptor. In mice, injection of IL-23 leads to epidermal hyperplasia mediated by IL-22 produced by IL-17-expressing T cells, 18, 19 and consistent, if not identical, phenomena are observed in humans. 20 Keratinocytes express high levels of IL-22 receptors, and are highly responsive to IL-22 as well as other cytokines of the IL-20 subfamily, including IL-19, IL-20 and IL-24.
21,22 IL-22 is distinctive among these cytokines in that it is primarily expressed by activated T cells and not keratinocytes, 23 and is therefore wellpositioned as a bridge between the two. We have recently implicated interferon-g (IFN-g) as a key stimulus causing CD14 þ macrophages to stimulate the proliferation of IL-17 þ T cells through their production of IL-1 and IL-23 24 ( Figure 1) . We also identified a population of CD8þ IL-17-expressing cells in the epidermis of psoriatic lesions. Essentially, all of the IL-17-producing T cells in the psoriatic epidermis were CD8þ , whereas there were no such cells in normal epidermis. 24 These cells may play a causal role in provoking epidermal hyperplasia in psoriasis, as recent studies in xenografted mice have shown that entry of T cells into the epidermis is necessary for development of the epidermal hyperplastic response. 25 
Genome-wide association scan of psoriasis
With the advent of the HapMap, 26 we now have a dense map of millions of single nucleotide polymorphisms (SNPs) to choose from, and massive throughput genotyping technologies allow 100 000-1 000 000 SNPs to be characterized economically in thousands of individuals. Anticipating these developments, in 2003, we refocused our experimental approach from linkage to association, opting to collect large numbers of cases and controls rather than families. In 2006, we formed a multicenter collaboration with Dr Anne Bowcock at Washington University of St Louis and Dr Gerald Krueger of the University of Utah, to carry out a genome-wide association study (GWAS) of psoriasis (the Collaborative Association Study of Psoriasis or CASP). We were funded by the Genetic Association Information Network (GAIN), a public-private partnership formed to facilitate the execution of GWAS and the rapid dissemination of their results. 27 We also linked up with five additional groups of collaborators interested in psoriasis vulgaris and PsA to carry out a powerful replication study on the basis of the GAIN results. The results of this study have been published recently 28 and will be briefly reviewed here.
We carried out a GWAS of 1409 Caucasian psoriasis cases and 1436 Caucasian controls, making use of a Perlegen Sciences microarray platform (Perlegen Sciences, Mountain View, CA, USA) that types a large number of SNPs with known effects on protein structure and gene expression, and allows for efficient incorporation of HapMap tag SNPs. After removing SNPs and samples with low genotype call rates, screening for related individuals and removing markers with strong deviations from Hardy-Weinberg equilibrium, we carried out our initial association analysis on 438 670 SNPs in 1539 cases and 1400 controls. By far, the strongest association signals mapped to the MHC (Figure 2 ). SNP rs12191877, the marker showing the strongest association with psoriasis (f control ¼ 0.15, f case ¼ 0.30, odds ratio (OR) follow-up ¼ 2.64, P combined 510 À100 ), was in linkage disequilibrium (LD) with HLA-Cw6 (r 2 ¼ 0.63). Nearly equally strong signals were observed in the vicinity of corneodesmosin, as expected from our earlier studies of the MHC in psoriasis families. 29 In a subset of cases and controls with HLA-Cw6 typing, this allele was more strongly associated with psoriasis than any other genotyped or imputed SNP, but could not fully account for all observed association signals. We used a forward selection procedure to assess the possibility that multiple psoriasis susceptibility alleles might exist within the MHC. This analysis resulted in a model with three imputed SNPs. The first two of these (rs12204500 and rs13191343, forward selection P-values of 8 Â 10 À57 and 2 Â 10 À10 , respectively) are close to and in strong LD with HLA-Cw6 (r 2 ¼ 0.78 and 0.52, respectively). However, the third SNP (rs2022544, P-value ¼ 10
À7
) maps closer to the HLA-DR gene cluster in the C6orf10 gene and exhibits only weak LD with HLA-Cw6 (r 2 ¼ 0.01). These results confirm the predominance of the PSORS1 in terms of the magnitude of its genetic effect, and suggest that at least one additional determinant of psoriasis susceptibility resides within the MHC. This would be consistent with studies showing a higher risk associated with an extended ancestral haplotype carrying HLA-Cw6, HLA-B57 and HLA-DR4, relative to other HLA-Cw6-bearing haplotypes. 29, 30 On the basis of our initial genome-scan results, 21 SNPs representing 18 independent loci were genotyped in independent samples totaling 5048 cases and 5051 controls (1642 cases and 1101 Caucasian controls from the Michigan, 718 cases and 1464 controls from Kiel, Germany 981 cases and 925 controls from Celera Genomics, 302 cases and 500 controls from St Louis, 691 cases and 217 controls from Toronto, and 368 cases and 358 controls from Newfoundland) as well as a pedigree-based collection from France (1130 individuals from 45 families ranging from 5 to 60 members). Followup genotyping results confirmed association at seven loci (with Po10 À3 in the replication study and Po10
À8
overall), including three loci associated earlier with psoriasis, HLA-C, IL12B, IL23R, 28,31-33 and four new loci located near plausible psoriasis candidate genes, IL23A, IL4/IL13, TNFAIP3 and TNIP1. We next assessed the risk of PsA conferred by these replicated loci. As shown in Table 1 , three loci reached genome-wide significance for PsA compared with normal controls (HLA-C, IL12B and TNIP1) and one came close (IL4/IL13). Three loci manifested a statistically significant difference (Po0.05) between PsA and purely cutaneous psoriasis, HLA-C, IL12B and IL23R.
With the probable exception of HLA-Cw6, 29 the precise genetic variants responsible for the remaining six observed associations remain to be determined. Nevertheless, our results suggest roles for several key immunological pathways in disease susceptibility.
HLA-Cw6
HLA-C plays a key role in the presentation of antigens to CD8þ T cells, which predominate in the epidermis of psoriatic lesions. Guttate eruptions frequently follow attacks of streptococcal pharyngitis. 5 Other streptococcal skin infections, such as erysipelas, impetigo or cellulitis, do not seem to trigger psoriasis, suggesting a critical role for the tonsils. Tonsillar T cells recognize activated skin endothelium, 34 and home to the skin. Indeed, the same skin-homing T-cell clones present in the tonsils are also found in the lesional skin of psoriatic patients. 35 Many of these clonally exapanded T cells are CD8þ . 36 Several other studies have also identified oligoclonal T-cell receptor rearrangements in psoriasis. [35] [36] [37] [38] [39] These findings support the notion that T cells originally stimulated in the tonsils may traffic into the skin, in which some of them become clonally expanded because of antigenic stimulation. However, the identity of the antigen(s) has remained elusive. One study identified several potential psoriasis antigens by expression cloning from psoriatic skin RNA. 40 However, peripheral blood T cells from normal controls reacted as strongly as T cells derived from psoriatic patients, 40 making the results hard to interpret. In another study, HLA-Cw6 preferentially presented crossreactive peptides derived from strepto- coccal M protein and the hyperproliferative keratin K17 to skin-homing CD8þ T cells, 41 suggesting that the evolution of guttate into chronic plaque psoriasis might reflect a transition from a self-limited response to streptococcus initiated in the tonsils, to a sustained response to homologous peptides derived from hyperproliferative skin keratins. 41 It has also been suggested that peptidoglycan (PG), the major constituent of the streptococcal cell wall, acts as a T-cell activator in psoriasis. 42 PG-containing cells were detected in CD68 þ macrophages in the dermal papillae, and cellular infiltrates of guttate and chronic plaque skin lesions. 42 On the basis of these results, it has been proposed that macrophages may serve as a vehicle for transportation of PG from the tonsils to the skin, in which it may serve both as an antigen and as a stimulus for Toll-like receptor-mediated stimulation of innate immunity. 43 Whatever the antigen(s) may be, it is important to realize that most T cells present in psoriatic skin are not clonally expanded, indicative of important roles for additional mechanisms to maintain the psoriatic infiltrate.
HLA-C also plays a role in binding to killer immunoglobulin-like receptors (KIRs) on natural killer (NK) cells, and KIR genes have earlier been associated with PsA. 44, 45 NK cells are major producers of IFNs, and serve as a bridge between innate and acquired immunity. KIR molecules can either inhibit or stimulate NK cells, and inhibitory KIR genes interact with a dimorphic allotype (Asn80/Lys80) are present on HLA-C molecules. 46 HLACw6 is one of several 'group 2' alleles carrying Lys at position 80, thus one might expect that a combination of all 'group 2' alleles would provide a stronger association signal than does HLA-Cw6, but this is not the case (our unpublished data). Thus, at present, the role of HLACw6 as a mediator of in NK cell activity in psoriasis remains to be genetically clarified through typing of both KIRs and HLA-C in a large dataset.
IL-23 signaling
Three SNPs exhibiting strong evidence of association map near IL12B (encoding the p40 subunit of IL-23 and IL-12), IL23A (encoding the p19 subunit of IL-23) and IL23R (encoding a subunit of the IL-23 receptor) (see Nair et al. 28 for details). Our study implicated genetic variants in the IL23A locus for the first time in psoriasis and for that matter in any human autoimmune disorder. Interestingly, our GWAS identified no associations with either of the IL-12-specific genes, IL12B or IL12RB2, and psoriasis lesions markedly overexpress IL-12/23 p40 and IL-23 p19, but not IL-12 p35. 47 IL-23 signaling promotes cellular immune responses by promoting the survival and expansion of a recently identified subset of T cells expressing IL-17, which protects epithelia against microbial pathogens.
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Dysregulated IL-23 signaling could lead to inappropriate, chronic immune responses that target epithelial cells, perhaps helping to explain the relatively skin-specific inflammation seen in psoriasis. One of the same genetic variations in the IL23R gene that increases risk for psoriasis also confers risk for Crohn's Disease, 49 a disorder that has long been known to be clinically associated with psoriasis. 50 It is possible that this clinical association reflects the similarities between the epithelial linings of the skin and the gut.
NF-kB signaling
The products of the TNFAIP3 and TNIP1 genes (A20 and ABIN1/Naf1a, respectively), physically interact with each other to influence the ubiquitin-mediated destruction of IKKg (IkB kinase-g)/NEMO (NF-kB essential modulator), a central nexus of NF-kB signaling. 51 A20 also regulates the degradation of several other components of the tumor necrosis factor (TNF) signaling pathway. 51 TNF-a blockade improves the symptoms in a mouse model of psoriasis induced by administration of IL-23, 52 and a region of mouse chromosome 10 encompassing Tnfaip3 promotes psoriasis in a TNF-a dependant manner in another mouse model. 53 This region of the mouse genome has been also associated with atherosclerosis, 54 a major comorbidity of psoriasis. 55 Common polymorphisms near TNFAIP3 have recently been associated with systemic lupus erythematosus 56, 57 and with rheumatoid arthritis. 58, 59 Notably, the polymorphisms implicated in rheumatoid arthritis and systemic lupus erythematosus show no association with psoriasis in our sample (all P40.30) and are not in LD (all r 2 o0.03) with the psoriasis-associated alleles, suggesting that each of these common autoimmune diseases is driven by a different variant of the TNFAIP3 gene. Some of the polymorphisms implicated in rheumatoid arthritis and systemic lupus erythematosus reside far upstream from the gene (B200 kb), suggesting that they might reflect the existence of regulatory variants.
Th2-predisposing genes IL-13 and IL-4 are products of Th2 cells, which play a multifaceted role in allergic reactions and in the immune response to extracellular pathogens. Both IL-13 and IL-4 are expressed at high levels in atopic dermatitis, but only at very low levels in psoriasis. 60 IL-4 treatment has led to significant clinical improvement of psoriasis. 61 The IL13 and IL4 genes are located within 12.5 kb of each other on human chromosome 5q31.1, just telomeric to the RAD50 gene, within a block of LD. Although our most positive signals reside near IL4 and IL13, positive signals are also found in RAD50. Thus, the functional variant could influence not just IL13 but alternatively or in addition might influence IL4 and RAD50. Interestingly, a locus control region regulates the transcription of both IL13 and IL4 within the RAD50 gene. 
Immuno-genetic model for the development of psoriasis
During an initial flare of guttate psoriasis following a strep throat, we envision that T cells encounter streptococcal antigens presented in the context of HLA-Cw6 in the tonsils, in which they proliferate, differentiate into an effector/memory phenotype and acquire skin homing capability (that is, become cutaneous leukocyte antigen (CLA þ )). Upon entering the skin, these cells encounter a locally activated dermal environment characterized by capillary dilatation and edema, [63] [64] [65] [66] and the presence of plasmacytoid dendritic cells. 67, 68 We suspect that this 'pre-psoriatic environment' may be initiated by focal mast cell degranulation, and activation of plasmacytoid dendritic cells and macrophages, with release of TNF-a and IFN leading to induction of adhesion molecules on the endothelial cell surface, facilitating entry of T cells into the dermis. These events might be triggered by circulating pathogen-derived factors, such as PG, 43 and/ or innate immune mediators induced by them. Many of the signaling pathways are mediated by TNF-a, toll-like receptors, or other ligands, and receptors of the TNF receptor family that pass through NF-kB, often by way of IKK-g. Thus, genetically mediated defects in TNFAIP3 and TNIP1 could enhance this early inflammatory stage of lesion development by interfering with normal negative feedback regulation of NF-kB signaling.
At this early stage of lesional evolution, epidermal changes are subtle, but include a modest increase in keratinocyte DNA synthesis, widened extracellular spaces between keratinocytes and biochemical alterations in the stratum corneum, indicative of altered differentiation, despite a lack of visible parakeratosis. 69 These epidermal changes may be provoked by macrophage-derived proteases, creating holes in the epidermal basement membrane, 70 ,71 allowing permeation of fibronectin 72 and cytokine-laden mast cell granules into the epidermis. 73 These events could be hyperactive in psoriasis because of defective negative feedback regulation of signaling by TNFAIP3 and TNIP1. Keratinocyte hyperplasia results in the activation of a set of genes involved in regenerative hyperplasia, including keratins K6, K16 and K17, 74, 75 along with many other genes involved in innate immunity, including human bdefensin-2 (hBD-2), psoriasin (S100A7, S100A8 and S100A9), small proline-rich region (SPRR) proteins and late cornified envelope (LCE) proteins. 76, 77 Many of the most strongly upregulated genes in psoriasis are located in the epidermal differentiation complex on chromosome 1q21.3, also known as PSORS4, because of several reports of genetic linkage and association of this region to psoriasis. [78] [79] [80] [81] [82] It is also notable that the defensin gene cluster on human chromosome 8p exists in different copy numbers in different individuals, and psoriasis has been associated with increasing defensin gene copy number. 83 Once their expression has been turned on, peptides derived from these regenerative hyperplasia-associated proteins might serve as neoantigens on the surface of epidermal keratinocytes in the context of HLA Class I molecules, such as HLA-Cw6. It is also possible that Strep-derived PG could be delivered from the tonsils to the skin by macrophages, in which they would be recognized as foreign antigens and/or promote innate immune responses through binding to toll-like receptor2. 43 In the latter setting, downstream inflammatory signals could again be amplified as a consequence of TNFAIP3 and/or TNIP1 hypofunction.
As a consequence of streptococcal infection, the pool of T cells responding to streptococcal antigens will be expanded and activated. CD4 þ and CD8þ T cells will enter the dermis through the inflamed endothelium. A subset of both CD4 þ and CD8þ cells will express IL-17 and/or IL-22 because of stimulation by IL-23 and IL-1. Genetically mediated hyperfunction of IL-23 and/or of its receptor could enhance the production of IL-17-expressing T cells. Moreover, development of Th1 bias might be facilitated by genetically mediated hypofunction of the IL4 and IL13 genes. This would be predicted to lead to overproduction of IFN-g, a major product of Th1 cells. We have shown that IFN-g markedly stimulates the production of IL-23 by myeloid antigen-presenting cells (APC), 24 and IL-23 in turn supports the development of T cells expressing IL-17 and/or IL-22 (Figure 1) .
Many of the CD8þ cells entering the skin will selectively traffic to the epidermis, because they express VLA-1 as well as integrin a E b 7 , which binds to Ecadherin expressed by keratinocytes. 25, 84 Once in the epidermis, a subset of Strep-reactive CD8þ T cells is predicted to recognize self-derived or streptococcal peptides in the context of HLA-Cw6, thus maintaining immunological activation in an antigen-driven manner. We envision that a transition of reactivity from Strepderived to self proteins might be necessary for the transition from guttate to chronic plaque psoriasis. Whatever the nature of the antigen, entry of CD8þ T cells into the epidermis would trigger more extensive epidermal hyperplasia, possibly by means of cytokines, such as IL-17 and/or IL-22, produced by epidermal CD8þ T cells. [18] [19] [20] 24 Macrophages may also participate in this process, as suggested by two different mouse models of psoriasis, 85, 86 but it is important to remember that the development of extensive epidermal hyperplasia in the human skin xenograft model requires entry of T cells into the epidermis. 25 CD8þ T cells could also trigger the local release of a variety of soluble factors other than or in addition to IL-17 and/or IL-22, including cytokines, such as TNF-a, chemokines, such as IL-8 and CCL20, eicosanoids, and/or other innate immune mediators, which could further increase local inflammation and stimulate keratinocyte proliferation. 87 Whether mediated by soluble factors or by actual physical damage, keratinocytes could respond to T cell insult by elaborating growth factors such as amphiregulin, thereby encouraging their own proliferation and survival. 88 Concomitant with the induction of increased epidermal hyperplasia, there will be further upregulation of keratinocyte-derived innate immune peptides with antimicrobial and chemotactic activity, such as human b-defensin 2, CCL20, S100A7, S100A8 and S100A9, thus further increasing the number of immune and inflammatory cells entering the lesion, including neutrophils.
As summarized in Figure 3 , we envision the psoriatic tissue reaction as a multistage process, with the recognition of antigen in the context of HLA-Cw6 by CD8þ T cells playing a major role. This recognition probably takes place not only on APC, but also on the surface of keratinocytes. Genetic alterations in the TNFAIP3 and TNIP1 genes may play very important roles in APC and macrophages because of the central role of these genes in regulating NF-kB signaling. Genetic variation in IL12B, IL23A and IL23R may contribute to hyperexpansion of T cells expressing IL-17 and/or IL-22, and this process is further supported by IFN-g-producing Th1 cells whose polarization is influenced by genetically mediated hypofunction of IL-4 and/or IL-13. Entry of CD8þ T cells expressing IL-17 and/or IL-22 into the epidermis may provoke epidermal hyperplasia, leading to the overexpression by keratinocytes of many proteins involved in innate immunity. At least some of these may serve a source of antigen as well. Thus, the epidermal response 'feeds back' into all earlier stages of the psoriatic developmental process, amplifying the psoriatic tissue response. On the basis of the model shown in Figure 3 , the psoriasis susceptibility genes that we and others have identified so far seem to fit very well with current concepts of its immunopathogenesis.
Future prospects
Much additional work is required to identify the actual disease-predisposing variants of these genes and to understand how they contribute to pathology. Moreover, as can be seen in Figure 2 , additional genes remain to be discovered. Currently, we are carrying out a deeper follow-up scan of approximately 10 000 SNPs in approximately 3000 cases and 3000 controls to identify additional psoriasis loci. Moreover, we expect that the number of psoriasis genes that can be found will increase substantially as sample size grows through collaboration and continued subject enrollment. For example, work on lipids progressed from one new locus in a B2800 sample GWAS 89 to seven new loci in an B8800 sample GWAS, 90, 91 and now seven to nine additional loci from a B20 000 sample GWAS (Goncalo R Abecasis, unpublished data). Another example is human height, in which two initial GWAS identified one gene each, 92, 93 and subsequent larger GWAS and meta-analysis 92, 94 expanded the number of loci to nearly 40. Similar stories are playing out for other traits, notably Crohn's disease, in which a recent study of B14 000 samples identified a total of 32 confirmed loci, 21 of which were new. 95 Even if the risk conferred by the variants uncovered by larger GWAS is relatively small, these genes may constitute very good therapeutic targets. We already know that monoclonal antibodies directed against TNF-a and IL/ 12/23 p40 provide highly efficacious therapeutic regimens for many psoriasis patients, 96, 97 meaning that five of the genes implicated in our GWAS (IL12B, IL23A, IL23R, TNFAIP3 and TNIP1) play key roles in pathways targeted by therapeutic interventions. We expect that as new psoriasis susceptibility genes are identified, many of them will further illuminate these pathways and discover new ones amenable to therapeutic intervention. Moreover, once the full catalog of psoriasis genes have been identified, it may be possible to generate a 'psoriasis gene profile' that can accurately predict one's risk of developing psoriasis. We have already been able to show a 25-fold difference in risk depending upon how many disease alleles one inherits at the HLA-C and IL12B loci. 98 Finally, as illustrated by IL23R in Crohn's disease and by TNFAIP3 in rheumatoid arthritis and systemic lupus erythematosus, genetic insights into psoriasis may contribute to the better understanding of a variety of autoimmune and inflammatory disorders. Thus, continuing the search for psoriasis genes seems well worthwhile.
